Skip to the page

Data / Drug companies / Nexus Pharmaceuticals LLC

Nexus Pharmaceuticals LLC: 27 products in the FDA NDC directory, labeler code 14789

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Nexus Pharmaceuticals LLC (labeler code 14789) lists 27 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 27 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 30, 2026.

The request: Watch Nexus Pharmaceuticals LLC (FDA labeler code 14789): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
14789
Products in commercial distribution
27
Packages
30
Finished drugs by generic name
15
Prescription products
27
Over the counter products
0
Controlled substance products
Schedule IV 2
Flagged as original packager
27 of 27 products that carry the flag
Started marketing in the last 12 months
3
Earliest marketing start
October 14, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)2177.8%
Other unapproved drugs311.1%
New drug applications (NDA)311.1%

Products by type

TypeProductsShare
Prescription drugs27100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection2177.8%
Injection, solution622.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Cyclophosphamide14789-126InjectionGeneric drugs (ANDA)March 30, 2026
Cyclophosphamide14789-125InjectionGeneric drugs (ANDA)March 30, 2026
Tacrolimus14789-135InjectionGeneric drugs (ANDA)December 1, 2025
Methylene Blue14789-119Injection, solutionGeneric drugs (ANDA)February 1, 2025
Tranexamic Acid14789-115Injection, solutionGeneric drugs (ANDA)June 25, 2024
Phenobarbital Sodium14789-128Injection, solutionOther unapproved drugsDecember 6, 2023
Phenobarbital Sodium14789-127Injection, solutionOther unapproved drugsDecember 6, 2023
Fluorescein14789-123InjectionGeneric drugs (ANDA)October 24, 2023
Fluorescein14789-122InjectionGeneric drugs (ANDA)October 24, 2023
Tirofiban Hydrochloride14789-102InjectionGeneric drugs (ANDA)September 25, 2023
Tirofiban Hydrochloride14789-101InjectionGeneric drugs (ANDA)September 25, 2023
Emerphed PFS14789-252InjectionNew drug applications (NDA)March 1, 2023
Emerphed PFS14789-251InjectionNew drug applications (NDA)March 1, 2023
Baclofen14789-161InjectionGeneric drugs (ANDA)February 22, 2023
Papaverine Hydrochloride14789-121InjectionOther unapproved drugsJune 28, 2021
Potassium Chloride14789-109InjectionGeneric drugs (ANDA)February 28, 2021
Potassium Chloride14789-108InjectionGeneric drugs (ANDA)February 28, 2021
Potassium Chloride14789-107InjectionGeneric drugs (ANDA)February 28, 2021
Levetiracetam in Sodium Chloride14789-330InjectionGeneric drugs (ANDA)July 20, 2020
Levetiracetam in Sodium Chloride14789-220InjectionGeneric drugs (ANDA)July 20, 2020
Levetiracetam in Sodium Chloride14789-110InjectionGeneric drugs (ANDA)July 20, 2020
Emerphed14789-250InjectionNew drug applications (NDA)May 15, 2020
Arsenic Trioxide14789-600InjectionGeneric drugs (ANDA)November 19, 2018
Isoproterenol Hydrochloride14789-015Injection, solutionGeneric drugs (ANDA)August 3, 2017
Isoproterenol Hydrochloride14789-011Injection, solutionGeneric drugs (ANDA)August 3, 2017

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.